Health ❯ Healthcare ❯ Pharmaceuticals

Biosimilars

Drug Approval Regulatory Approvals Cancer Treatment FDA Approval Enzeevu™ Ophthalmology Rheumatoid Arthritis Treatments Tyruko Stelara Biosimilar Drugs Keytruda Insulin Glargine User Fees Ustekinumab Drug Pricing Regulatory Changes FDA Approval Process Regulatory Guidance FDA Guidance Regulations Insulin Starjemza Respiratory Drugs Gotenfia Pertuzumab-dpzb Market Opportunities Insulin Products Teva Pharmaceuticals Nufymco Product Portfolio Immuno-Oncology Regulatory History Clinical Data Safety Profile Semaglutide Teva Pharmaceutical Industries Synthetic Drugs Market Authorization Bosaya™ and Vezuo™ Yesintek Oral Semaglutide Ranibizumab

FDA Clears First Biosimilars to Simponi and Simponi Aria: IMMGOLIS and IMMGOLIS INTRI

The move opens biosimilar competition to Johnson & Johnson’s golimumab brands in arthritis and colitis care.

FDA Approves Langlara as Interchangeable Biosimilar to Lantus

FDA Clears Teva’s Ponlimsi, a Prolia Biosimilar, for All Indications

Zydus to Commercialize FDA-Approved Interchangeable Lucentis Biosimilar NUFYMCO in U.S. Under Bioeq Deal

FDA Approves Poherdy as First Interchangeable Biosimilar to Perjeta for HER2-Positive Breast Cancer